Dr Christopher Green MBBS, BMedSci(Hons), DTM&H, MRCP(ID), DPhil(Oxon)

Christopher Green

Institute of Microbiology and Infection
Senior Clinical Lecturer & Consultant Physician in Infectious Diseases

Contact details

Telephone
0121 414 3113
Email
c.a.green.2@bham.ac.uk
View my research portal
Address
Biosciences Building, Room W112
Institute of Microbiology and Infection
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Christopher Green divides his time between working as an Infectious Diseases physician in the NHS and as an academic/clinical researcher with the University. His main research interests are in translational medicine, vaccines development, understanding the immune response to infection/vaccination, and in new approaches to the problem of antimicrobial resistance.

Qualifications

  • Certificate of Completion of Training (CCT) in Infectious Diseases and General (Internal) Medicine 2018 
  • Doctor of Philosophy (DPhil), University of Oxford 2017
  • Member of the Royal College of Physicians (MRCP), Royal College of Physicians 2010
  • Diploma in Tropical Medicine & Hygiene (DTMH), Royal College of Physicians 2008 
  • Bachelor of Medicine and Bachelor of Surgery (MBBS), University of Newcastle upon Tyne 2004
  • Bachelor of Medical Science (BMedSci) with 2:1 honours in Visual Neuroscience, University of Newcastle upon Tyne 2002

Biography

Christopher Green works as both a practicing Infectious Diseases physician in the NHS and an academic researcher within the IMI. His NHS work takes him to the front line of acute care and his speciality medicine work focusses on the diagnosis and management of complex infection (such as drug-resistant infections, post-surgical infection), infection in immune compromised patients (such as HIV and transplant recipients) and infections imported from overseas (such as TB and malaria). During his clinical training he was fortunate to be seconded to the University of Oxford to further develop his interests in research and vaccinology.

His ongoing research interests include the development of new and novel vaccines through clinical trials, understanding the host immune response to infection/vaccination, investigating faecal microbiota transplantation, and in using technology to mitigate the increasing problem of drug-resistant bacterial infections in clinical care.

Teaching

  • Year 2 MBChB course IIH module; lecturer and small group tutor, University of Birmingham
  • Year 3 MBChB course CC2 module; lecturer and infection teaching lead, University of Birmingham
  • Year 4 MBChB course SSM module deputy lead, University of Birmingham
  • Year 4-5 MBChB course bedside clinical teaching, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust
  • Clinical and Educational supervisor, University Hospitals Birmingham NHS Foundation Trust

Research

  • Clinical trials of new and novel vaccines
  • Understanding the immune response to infection/vaccination
  • Faecal microbiota transplantation

Other activities

  • Consultant Physician (Infectious Diseases & General Medicine), University Hospitals Birmingham NHS Foundation Trust
  • Clinical Research Specialty Lead for Infection & Immunology, West Midlands NIHR Clinical Research Network

Publications

Horby PW, Wei Shen L, Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi W, Prudon B, Green CA, Felton T, Chadwick D, Rege K, Fegan C, Chappell L, Fuast SN, Jaki T, Jeffry K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Effect of dexamethasone in hospitalised patients with Covid19 - preliminary report.  New England Journal of Medicine. July 17 2020.

Docherty AB, Harrison EM, Green CA, Hardwick H, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russel CD, Dunnng J, Openshaw PJM, Baillie JK, Semple MG. Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.  British Medical Journal.  2020;369:m1985. 2020 May 22.

Moran E, Robinson E, Green CA, Keeling M, Collyer B. Towards personalised guidelines: using machine-learning algorithms to guide antimicrobial selection.  Journal of Antimicrobial Chemotherapy. 2020 June 15.

Green CA, Sande CJ, Scarselli E, Capone S, Vitelli A, Nicosia A, Silva-Reyes L, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Hutchings CL, Cargill T, Angus B, Klenerman P, Pollard AJ. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.  Journal of infection. 2019;78(5):382-392.

Sande CJ, Njunge JM, Mwongeli J, Mutunga MN, Chege T, Gicheru E, Gardiner E, Gwela A, Green CA, Drysdale SB, Berkley JA, Nokes DJ, Pollard AJ. Airway response to respiratory syncytial virus has incidental antibacterial effects. Nature Communications. 2019 May 17; 10 (1):2218

Green CA, Sande CJ, de Lara C, Thompson AJ, Silva-Reyes L, Napolitano F, Pierantoni A, Capone S, Vitelli A, Klenerman P, Pollard AJ. Humoral and cellular immunity to RSV in infants, children and adults. Vaccine. 2018 Aug 31.

Gerretsen HE, Vitelli A, Capone S, Silva-Reyes L, Thompson AJ, Jones CJ, Green CA, Pollard AJ, Sande CJ.  Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies incuded by RSV vaccination and pre-existing antibodies induced by natural infection. Vaccine. 2018 Oct 11.

Green CA, Yeates D, Goldacre A, Sande C, Parslow RC, McShane P, Pollard AJ, Goldacre MJ. Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Archives of Diseases in Childhood. 2016 Feb; 101(2):140-6.

Darton TC, Jones C, Blohmke CJ, Wadington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jepperson CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Neglected Tropical Diseases. 2016 August 17;10(8):e0004926.

Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KDS, Haworth K, Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori A, Colloca S, Capone S, Vitelli A, Cortese R, Klenerman P, Nicosia A, Pollard AJ. Chimpanzee adenovirus-and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Science Translational Medicine. 2015 Aug 12;7(300):300ra126.

Marsay L*, Dold C*, Green CA*, Rollier CS, Norheim G, Sadarangani M, Shanyinde M, Brehony C, Thompson AJ, Sanders H, Chan H, Haworth K, Derrick JP, Feavers IM, Maiden MC, Pollard AJ (*shared first author position). A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. Journal of Infection. 2015 Sep;71(3):326-37

Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, Cortese R, Thompson AJ, Sande CS, de Lara C, Klenerman P, Pollard AJ. Safety and Immunogenicity of novel respiritaory synctial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open. 2015 Oct 28;5(10):e008748

View all publications in research portal